Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a new vaccine beat chickenpox? large trial underway

NCT ID NCT07415252

Vaccine Sponsor: SK Bioscience Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 16, 2026 · Updated 2 times

Summary

This study tests a new chickenpox vaccine called NBP608 in about 780 children aged 1 to 12 years. The vaccine is compared to licensed vaccines to see how well it triggers immunity and if it is safe. Children receive one or two shots, and researchers monitor their immune response over 15 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
NBP608 (live attenuated varicella virus vaccine)
What this could lead to
If successful, this could provide a safe and effective alternative chickenpox vaccine for children.
What could go wrong
This is a phase 3 trial, but results may not show superiority over existing vaccines. Side effects are possible, as with any vaccine.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 780 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 months to 12 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Participant must be ≥12 months to ≤12 years of age, at the time of informed consent. 2. Participant is healthy or medically stable, as determined by the investigator through medical history, physical examination, and overall clinical assessment. 3. Participant's parents/LARs are able and willing to comply with all study procedures and attend all scheduled visits. 4. Female participants of childbearing potential must agree to comply with applicable contraceptive requirements as defined in the protocol. 5. Female participants of a childbearing potential must have a negative urine pregnancy test at screening; pregnancy testing is not required for those not of childbearing potential. 6. Participant's parents/LARs are capable of providing signed informed consent, including agreement to comply with the requirements and restrictions specified in this protocol and in the informed consent form (ICF), before initiation of any study-specific procedures. Where applicable, the participant must also be able to provide written assent in accordance with local regulations and IRB/IEC requirements. Exclusion Criteria: 1\. Participants with any acute illness, including fever or clinically significant symptoms, at the time of study vaccination. 2. History of varicella-zoster virus (VZV) infection or recent exposure to VZV. 3\. Presence of household contacts at high risk for severe VZV infection 4. History of immunodeficiency, autoimmune disease, or other conditions affecting the immune system. 5\. History of bleeding disorders contraindicating vaccination. 6. History of severe allergic reactions to vaccines or vaccine components. 7. History of Guillain-Barré syndrome associated with prior vaccination. 8. Active untreated tuberculosis infection. 9. Any significant medical condition that, in the investigator's judgment, may interfere with study participation or interpretation of results. 10\. Prior receipt of any varicella-containing vaccine. 11. Receipt or planned use of vaccines, medications, immunoglobulins, blood products, or immunosuppressive therapies that may interfere with study evaluation, as defined in the protocol. 12\. Participation in another clinical study involving an investigational intervention within a protocol-defined timeframe. 13\. Study staff, investigators, and their immediate family members.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Varicella (chickenpox) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chickenpox prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Varicella (chickenpox)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    14 sites in 4 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ansan, site 401

    RECRUITING

    Ansan, Gyeonggi-do, 15355, South Korea

  • Daegu, site 404

    RECRUITING

    Daegu, Daegu, 42601, South Korea

  • Hwaseong-si, site 406

    NOT_YET_RECRUITING

    Hwaseong-si, Gyeonggi-do, 18450, South Korea

  • Incheon, site 403

    RECRUITING

    Incheon, Incheon, 21431, South Korea

  • Khon Kaen City, site 201

    NOT_YET_RECRUITING

    Khon Kaen, Changwat Khon Kaen, 40002, Thailand

  • Manila, site 301

    RECRUITING

    Manila, National Capital Region, 1000, Philippines

  • Quezon City, site 302

    RECRUITING

    Quezon City, National Capital Region, 1113, Philippines

  • Quezon City, site 303

    RECRUITING

    Quezon City, National Capital Region, 1118, Philippines

  • San Pedro Sula, site 101

    NOT_YET_RECRUITING

    San Pedro Sula, Cortés Department, 21104, Honduras

  • Seongnam-sit, site 405

    NOT_YET_RECRUITING

    Seongnam-si, Gyeonggi-do, 13620, South Korea

  • Seoul, site 402

    RECRUITING

    Seoul, Seoul, 02841, South Korea

  • Seoul, site 407

    NOT_YET_RECRUITING

    Seoul, Seoul, 08308, South Korea

  • Seoul, site 408

    NOT_YET_RECRUITING

    Seoul, Seoul, 07985, South Korea

  • Tegucigalpa, site 102

    RECRUITING

    Tegucigalpa, Francisco Morazán Department, 11101, Honduras

More trials for these conditions

Other studies related to the condition(s) this trial covers.